Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
May 09 2018 - 7:30AM
Amicus Therapeutics (Nasdaq:FOLD) today announced that John F.
Crowley, Chairman and Chief Executive Officer, will participate in
a fireside chat at the Bank of America Merrill Lynch 2018 Health
Care Conference in Las Vegas, NV on Tuesday, May 15, 2018 at 9:20
a.m. P.T.
A live webcast of the presentation can be
accessed through the Investors section of the Amicus Therapeutics
corporate web site at http://ir.amicusrx.com/events.cfm, and will
be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated
biotechnology company focused on discovering, developing and
delivering novel high-quality medicines for people living with rare
metabolic diseases. The cornerstone of the Amicus portfolio is
migalastat, an oral precision medicine for people living with Fabry
disease who have amenable genetic mutations. Migalastat is
currently approved under the trade name Galafold™ in the European
Union, with additional approvals granted and pending in several
geographies. The lead biologics program in the Amicus pipeline is
AT-GAA, a novel, late-stage, potential best-in-class treatment
paradigm for Pompe disease. The Company is committed to advancing
and expanding a robust pipeline of cutting-edge, first- or
best-in-class medicines for rare metabolic diseases.
CONTACTS:
Investors/Media:Amicus
TherapeuticsSara Pellegrino, IRCVice President, Investor Relations
& Corporate Communicationsspellegrino@amicusrx.com(609)
662-5044
Media:Pure CommunicationsJennifer Paganelli
jpaganelli@purecommunications.com (347) 658-8290
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Apr 2023 to Apr 2024